ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
코어 1 합성효소, C1GALT1 항체 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 6억 6,000만 달러로 평가되었고, 2025년에는 7억 3,000만 달러에 달할 것으로 추정되며, CAGR 10.3%로 성장이 전망되고 있습니다. 지난 수년간의 성장은 진단 분야에서의 단일클론 항체 사용 증가, 면역측정법의 보급 확대, 만성 질환 및 감염증 유병률 상승, 바이오의약품 연구 활동의 확대, 항체 기반의 창약에 대한 투자 증가에 기인한 것으로 보입니다.
코어 1 합성효소, C1GALT1 항체 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 10억 6,000만 달러에 달할 것으로 예측되며, CAGR 9.9%로 성장할 전망입니다. 예측 기간의 성장은 맞춤형 의료에 대한 수요 증가, 표적 치료 개발에 대한 주목 증가, 생명 공학 연구에 대한 자금 증가, 첨단 항체를 이용한 진단 용도 확대, 임상시험 및 트랜스 셔널 리서치에서 항체 사용 증가로 인한 것으로 예측됩니다. 예측 기간 주요 동향으로는 하이브리도마 및 파지 디스플레이 기술의 진보, 재조합 항체 공학에서의 지속적인 혁신, 항체 단편 생산 기술의 발전, 차세대 항체의 연구 개발, 자동화 및 고스루풋 항체 스크리닝 플랫폼의 출현 등을 들 수 있습니다.
만성 질환의 유병률 상승은 향후 코어 1 합성효소, C1GALT1 항체 시장의 성장을 가속할 것으로 예측됩니다. 만성 질환은 천천히 진행되고 장기간 지속되는 지속적인 건강 상태이며, 지속적인 의료 관리가 필요한 경우가 많습니다. 만성질환 증가는 앉기 쉬운 생활 및 운동부족과 같은 불활발한 생활 양식이 일부 요인이 되고 있으며, 장시간 계속 앉아있거나 신체 활동의 부족은 심장 질환 및 당뇨병 등의 리스크를 높입니다. C1GLT 항체는 C1GALT1의 발현을 정확하게 검출하고 모니터링할 수 있게 하며, 만성 질환의 관리를 강화합니다. 이를 통해 조사 및 진단 용도 분야에서 가치 있는 도구가 됩니다. 특이적이고 신뢰할 수 있는 결과를 제공함으로써 질병 평가의 불확실성을 줄이고, 치료 전략의 개선 및 환자 결과 개선에 기여합니다. 예를 들어 영국 정부 기관인 국민보건서비스(NHS)에 따르면 2024년 6월 시점에서 2023년 일반 개업의에 등록된 361만 5330명이 비당뇨병성 고혈당 또는 전당뇨병으로 진단되고 있으며 이는 2022년 306만 5825례에서 18% 증가했습니다. 따라서 만성 질환의 유병률 증가는 코어 1 합성효소, C1GALT1 항체 시장의 성장을 가속하고 있습니다.
암 이환율의 상승은 향후 코어 1 합성효소, C1GALT1 항체 시장의 성장을 가속할 것으로 예측됩니다. 암 이환율이란 특정 시점에서 새롭게 진단된 분과 이전에 진단된 분을 맞춘 암 경력이 있는 생존자의 총수를 말합니다. 부적절한 식생활, 흡연, 음주, 환경 오염물질에 대한 노출 등 생활 습관과 관련된 위험 요인에 의해 암 유병률은 증가하는 경향이 있어 다양한 암 발병위험을 높이고 있습니다. C1GLT 항체는 C1GALT1 발현의 정밀한 검출 및 모니터링을 가능하게 함으로써 암 관리를 지원하고 연구, 진단, 치료 개발에 유용합니다. 특이적이고 신뢰할 수 있는 결과를 제공함으로써 종양 평가의 불확실성을 줄이고 치료 전략 및 환자 결과를 개선합니다. 예를 들어 호주 정부 기관인 Cancer Australia에 따르면 2025년 2월 시점에서 2024년 신규 췌장암 증례 수는 4641례(남성 2414례, 여성 2227례)였습니다. 따라서 암 이환율의 상승이 코어 1 합성효소, C1GALT1 항체 시장의 성장을 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 코어 1 합성효소, C1GALT1 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 코어 1 합성효소, C1GALT1 시장 : 성장률 분석
세계의 코어 1 합성효소, C1GALT1 시장 실적 : 규모 및 성장(2019-2024년)
세계의 코어 1 합성효소, C1GALT1 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 코어 1 합성효소, C1GALT1 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 코어 1 합성효소, C1GALT1 시장 : 제품 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
단일클론 항체
폴리클로날 항체
재조합 항체
팹 단편
세계의 코어 1 합성효소, C1GALT1 항체 시장 : 기술별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
하이브리도마 기술
파지 디스플레이 기술
트랜스제닉 기술
유전 공학 기술
세계의 코어 1 합성효소, C1GALT1 항체 시장 : 소스별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
인간 유래
마우스 유래
토끼 유래
기타 동물 유래
세계의 코어 1 합성효소, C1GALT1 항체 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
바이오 사이언스 기업
병원 및 진료소
대학 및 연구기관
세계의 코어 1 합성효소, C1GALT1 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제약 및 생명 공학 기업
연구기관
병원 및 진단 실험실
학술기관
세계의 코어 1 합성효소, C1GALT1 시장 : 단일클론 항체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
하이브리도마 단일클론 항체
인간화 단일클론 항체
키메라 단일클론 항체
완전 인간 단일클론 항체
세계의 코어 1 합성효소, C1GALT1 시장 : 폴리클로날 항체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
토끼 폴리클로날 항체
염소 폴리클로날 항체
양 폴리클로날 항체
닭 다클론 항체
세계의 코어 1 합성효소, C1GALT1 시장 : 재조합 항체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
싱글 체인 가변 영역 항체
항원 결합 항체
이중특이성 재조합 항체
인간 재조합 항체
세계의 코어 1 합성효소, C1GALT1 시장 : 팹 단편 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
1가 Fab 단편
2가 Fab 단편
인간화 Fab 단편
키메라 Fab 조각
제7장 지역별 및 국가별 분석
세계의 코어 1 합성효소, C1GALT1 항체 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 코어 1 합성효소, C1GALT1 항체 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
코어 1 합성효소, C1GALT1 항체 시장 : 경쟁 구도
코어 1 합성효소, C1GALT1 항체 시장 : 기업 프로파일
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Wuhan Cusabio Biotech Co. Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
OriGene Technologies Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
RayBiotech Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
GeneTex Inc.
Santa Cruz Biotechnology Inc.
Atlas Antibodies AB
Bioss Inc.
Aviva Systems Biology Corporation
Arigo Biolaboratories Inc.
MyBioSource Inc.
Cosmo Bio USA Inc.
RD Systems Inc.
Boster Biological Technology Co. Ltd.
Abbexa Ltd.
BosterBio Inc.
LifeSpan BioSciences Inc.
EpiGentek Group Inc.
Leading Biolog Co. Ltd.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
코어 1 합성효소, C1GALT1 항체 시장(2029년) : 새로운 기회를 제공하는 국가
코어 1 합성효소, C1GALT1 항체 시장(2029년) : 새로운 기회를 제공하는 부문
코어 1 합성효소, C1GALT1 항체 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Core 1 synthase, glycoprotein N acetylgalactosamine 3 beta galactosyltransferase 1 (C1GLT) antibody is a specialized research antibody created to identify and bind to the C1GALT1 enzyme, an essential glycosyltransferase that produces core 1 O glycan structures in glycoproteins. It is widely used in scientific research to detect, measure, and study the expression levels of C1GALT1 in various cell types and biological tissues. This antibody contributes significantly to progress in molecular biology and biomedical research.
The main product types of core 1 synthase, glycoprotein N acetylgalactosamine 3 beta galactosyltransferase 1 (C1GLT) antibody are monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and fab fragments. Monoclonal antibodies are laboratory produced molecules created to bind specifically to a single antigen site on a target cell or pathogen. It uses various technologies such as hybridoma technology, phage display technology, transgenic technology, and gene engineering technology and is sourced from human sources, murine sources, rabbit sources, and other animal sources. It is applied in bioscience companies, hospitals and clinics, and universities and institutions, serving end users including pharmaceutical and biotechnology companies, research institutions, hospitals and diagnostic laboratories, and academic institutions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GLT) antibody market research report is one of a series of new reports from The Business Research Company that provides core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GLT) antibody market statistics, including core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GLT) antibody industry global market size, regional shares, competitors with a core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GLT) antibody market share, detailed core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GLT) antibody market segments, market trends and opportunities, and any further data you may need to thrive in the core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GLT) antibody industry. This core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GLT) antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GLT) antibody market size has grown rapidly in recent years. It will grow from $0.66 billion in 2024 to $0.73 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to rising use of monoclonal antibodies in diagnostics, increasing adoption of immunoassay techniques, growing prevalence of chronic and infectious diseases, expansion of biopharmaceutical research activities, and rising investments in antibody based drug discovery.
The core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GLT) antibody market size is expected to see strong growth in the next few years. It will grow to $1.06 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to rising demand for personalized medicine, increasing focus on targeted therapeutic development, growing funding for biotechnology research, expansion of diagnostic applications using advanced antibodies, and rising use of antibodies in clinical trials and translational research. Major trends in the forecast period include advancements in hybridoma and phage display technologies, ongoing innovations in recombinant antibody engineering, developments in antibody fragment production, research and development in next generation antibodies, and the emergence of automated and high throughput antibody screening platforms.
The rising prevalence of chronic diseases is expected to propel the growth of the core 1 synthase, glycoprotein N acetylgalactosamine 3 beta galactosyltransferase 1 (C1GLT) antibody market going forward. Chronic diseases are persistent health conditions that develop slowly and last for an extended period, often requiring continuous medical care. The growing prevalence of chronic diseases is partly due to inactive lifestyles, as prolonged sitting and minimal physical activity raise the risk of diseases such as heart conditions and diabetes. C1GLT antibody enhances chronic disease management by enabling precise detection and monitoring of C1GALT1 expression, making it valuable for research and diagnostic applications. It reduces uncertainty in disease assessment by providing specific and reliable results, improving treatment strategies and patient outcomes. For instance, in June 2024, according to the National Health Service, a UK based government department, 3615330 individuals registered with a general practitioner were diagnosed with non diabetic hyperglycemia or pre diabetes in 2023, marking an 18 percent increase from 3065825 cases in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the core 1 synthase, glycoprotein N acetylgalactosamine 3 beta galactosyltransferase 1 (C1GLT) antibody market.
The rising prevalence of cancer is expected to propel the growth of the core 1 synthase, glycoprotein N acetylgalactosamine 3 beta galactosyltransferase 1 (C1GLT) antibody market going forward. Prevalence of cancer refers to the total number of people, both newly diagnosed and previously diagnosed, who are alive with a history of cancer at a specific point in time. The prevalence of cancer is increasing due to lifestyle related risks such as poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, elevating the risk of developing various cancers. C1GLT antibody aids in cancer management by enabling precise detection and monitoring of C1GALT1 expression, making it valuable for research, diagnostics, and therapeutic development. It reduces uncertainty in tumor assessment by providing specific and reliable results, improving treatment strategies and patient outcomes. For instance, in February 2025, according to Cancer Australia, an Australia based government agency, there were 4641 new pancreatic cancer cases in 2024, with 2414 in males and 2227 in females. Therefore, the rising prevalence of cancer is driving the growth of the core 1 synthase, glycoprotein N acetylgalactosamine 3 beta galactosyltransferase 1 (C1GLT) antibody market.
The rising demand for personalized medicine is expected to propel the growth of the core 1 synthase, glycoprotein N acetylgalactosamine 3 beta galactosyltransferase 1 (C1GLT) antibody market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable the precise identification of genetic variations and tailored treatments for individuals. C1GLT antibody enhances personalized medicine by enabling precise detection and monitoring of C1GALT1 expression, making it valuable for tailoring treatments to individual patient profiles. It reduces uncertainty in therapy selection by providing specific and reliable biomarker data, improving treatment efficacy and patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US based nonprofit organization, the US Food and Drug Administration approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the core 1 synthase, glycoprotein N acetylgalactosamine 3 beta galactosyltransferase 1 (C1GLT) antibody market.
Major companies operating in the core 1 synthase, glycoprotein-n-acetylgalactosamine 3-beta-galactosyltransferase 1 (c1glt) antibody market are Merck & Co. Inc., Thermo Fisher Scientific Inc., Wuhan Cusabio Biotech Co. Ltd., OriGene Technologies Inc., RayBiotech Inc., GeneTex Inc., Santa Cruz Biotechnology Inc., Atlas Antibodies AB, Bioss Inc., Aviva Systems Biology Corporation, Arigo Biolaboratories Inc., MyBioSource Inc., Cosmo Bio USA Inc., RD Systems Inc., Boster Biological Technology Co. Ltd., Abbexa Ltd., BosterBio Inc., LifeSpan BioSciences Inc., EpiGentek Group Inc., Leading Biolog Co. Ltd.
North America was the largest region in the core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GLT) antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GLT) antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GLT) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GLT) antibody market consists of sales of antibody fragments, secondary antibodies, custom antibodies, antibody-drug conjugates, antibody kits, reagent vials, assay buffers, detection reagents, and western blot membranes. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on core 1 synthase, glycoprotein-n-acetylgalactosamine 3-beta-galactosyltransferase 1 (c1glt) antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for core 1 synthase, glycoprotein-n-acetylgalactosamine 3-beta-galactosyltransferase 1 (c1glt) antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The core 1 synthase, glycoprotein-n-acetylgalactosamine 3-beta-galactosyltransferase 1 (c1glt) antibody market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Monoclonal Antibodies; Polyclonal Antibodies; Recombinant Antibodies; Fab Fragments
3) By Recombinant Antibodies: Single Chain Variable Fragment Antibodies; Fragment Antigen Binding Antibodies; Bispecific Recombinant Antibodies; Human Recombinant Antibodies
4) By Fab Fragments: Monovalent Fab Fragments; Bivalent Fab Fragments; Humanized Fab Fragments; Chimeric Fab Fragments
Companies Mentioned: Merck & Co. Inc.; Thermo Fisher Scientific Inc.; Wuhan Cusabio Biotech Co. Ltd.; OriGene Technologies Inc.; RayBiotech Inc.; GeneTex Inc.; Santa Cruz Biotechnology Inc.; Atlas Antibodies AB; Bioss Inc.; Aviva Systems Biology Corporation; Arigo Biolaboratories Inc.; MyBioSource Inc.; Cosmo Bio USA Inc.; RD Systems Inc.; Boster Biological Technology Co. Ltd.; Abbexa Ltd.; BosterBio Inc.; LifeSpan BioSciences Inc.; EpiGentek Group Inc.; Leading Biolog Co. Ltd.
4. Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Growth Analysis And Strategic Analysis Framework
5.1. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.1. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Polyclonal Antibodies
Recombinant Antibodies
Fab Fragments
6.2. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hybridoma Technology
Phage Display Technology
Transgenic Technology
Gene Engineering Technology
6.3. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Human Sources
Murine Sources
Rabbit Sources
Other Animal Sources
6.4. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
BioScience Companies
Hospitals And Clinics
University And Institutions
6.5. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical and Biotechnology Companies
Research Institutions
Hospitals And Diagnostic Laboratories
Academic Institutions
6.6. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hybridoma Monoclonal Antibodies
Humanized Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Fully Human Monoclonal Antibodies
6.7. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market, Sub-Segmentation Of Polyclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rabbit Polyclonal Antibodies
Goat Polyclonal Antibodies
Sheep Polyclonal Antibodies
Chicken Polyclonal Antibodies
6.8. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market, Sub-Segmentation Of Recombinant Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single Chain Variable Fragment Antibodies
Fragment Antigen Binding Antibodies
Bispecific Recombinant Antibodies
Human Recombinant Antibodies
6.9. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market, Sub-Segmentation Of Fab Fragments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monovalent Fab Fragments
Bivalent Fab Fragments
Humanized Fab Fragments
Chimeric Fab Fragments
7. Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market Regional And Country Analysis
7.1. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Wuhan Cusabio Biotech Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. OriGene Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. RayBiotech Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market Other Major And Innovative Companies
31.1. GeneTex Inc.
31.2. Santa Cruz Biotechnology Inc.
31.3. Atlas Antibodies AB
31.4. Bioss Inc.
31.5. Aviva Systems Biology Corporation
31.6. Arigo Biolaboratories Inc.
31.7. MyBioSource Inc.
31.8. Cosmo Bio USA Inc.
31.9. RD Systems Inc.
31.10. Boster Biological Technology Co. Ltd.
31.11. Abbexa Ltd.
31.12. BosterBio Inc.
31.13. LifeSpan BioSciences Inc.
31.14. EpiGentek Group Inc.
31.15. Leading Biolog Co. Ltd.
32. Global Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market
34. Recent Developments In The Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market
35. Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market High Potential Countries, Segments and Strategies
35.1 Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market In 2029 - Countries Offering Most New Opportunities
35.2 Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1 (C1GLT) Antibody Market In 2029 - Segments Offering Most New Opportunities
